http://www.reuters.com/article/2013/10/31/tevapharm-results-idUSL5N0IL30220131031
specific quote:
"Kolbert said the only way to turn Teva around post-Copaxone was with another high-margin product, which he believes Teva has in a treatment developed by Mesoblast. Teva, Mesoblast's development and commercial partner, on Wednesday received clearance from the U.S. Food and Drug Administration to conduct advanced clinical trials in patients with chronic congestive heart failure."
http://www.reuters.com/article/2013/10/31/tevapharm-results-idUSL...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |